Pediatric Cancers | Topics

 
How to Treat Metastatic Malignant Triton Tumor in an Adolescent
November 21, 2022

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.

FDA Approves Brentuximab Vedotin for Previously Untreated High-Risk Pediatric Lymphoma
November 10, 2022

Patients with previously untreated high-risk pediatric lymphoma can now receive treatment with brentuximab vedotin with the FDA’s nod of approval.

Rare Pediatric Designation Granted by the FDA to Nomacopan for HSCT Thrombotic Microangiopathy
November 10, 2022

Findings from a phase 3 trial assessing nomacopan in patients with hematopoietic stem cell transplant–related thrombotic microangiopathy helped to support a rare pediatric designation from the FDA for the agent.

FDA’s ODAC Casts 16 to 0 Vote Against Omburtamab in Pediatric Metastatic Neuroblastoma
November 03, 2022

Members of the FDA’s Oncologic Drugs Advisory Committee indicated there isn’t enough evidence to definitively confirm the overall survival benefit of 131I-omburtamab in pediatric patients with central nervous system or leptomeningeal metastases stemming from neuroblastoma.

FDA Grants Orphan Drug Designation to ET140203 T Cells for Hepatoblastoma
October 19, 2022

The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.

FDA Approves Sodium Thiosulfate to Decrease Cisplatin-Associated Ototoxicity in Pediatric Localized, Non-Metastatic Solid Malignancies
September 21, 2022

Sodium thiosulfate, which appears to be effective in decreasing the risk for hearing loss related to treatment with cisplatin, received FDA approval in pediatric patients with localized, non-metastatic solid tumors.

Dual Targeted Treatment Improves Response Over Chemotherapy in BRAF V600+ Pediatric Low-Grade Glioma
June 06, 2022

BRAF V600 mutation–positive pediatric low-grade glioma positively responds to combination treatment with dabrafenib plus trametinib, according to data presented at 2022 ASCO.

Hispanic Patients With Pediatric Neuroblastoma May Have Worse OS Outcomes vs Other Ethnic Subgroups
May 27, 2022

Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.

FDA Approved Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
May 20, 2022

Based on the results of the AZA-JMML-001 trial, the FDA has approved azacitidine for use in newly diagnosed juvenile myelomonocytic leukemia.

Omburtamab BLA Re-Submitted to FDA for Pediatric Neuroblastoma
April 04, 2022

A biologics license application for omburtamab was resubmitted following a refusal to file letter in 2020 for pediatric patients with central nervous system/leptomeningeal metastatic from neuroblastoma.